Immunoglobulin News and Research

RSS

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

A new study discusses risk factors for the failure of seroconversion following full vaccination with the COVID-19 Pfizer vaccine.

18 Oct 2021

Common treatment for MIS-C patients likely works by depleting neutrophils

Intravenous immune globulin (IVIG) — a common treatment for multisystem inflammatory syndrome in children (MIS-C) — likely works by depleting immune cells called neutrophils, according to a recent study funded by the National Institutes of Health.

15 Oct 2021

SARS-CoV-2 induces tissue immune memory

A new study reports that the SARS-CoV-2 induces protective tissue memory that includes both humoral and cellular elements to protect specific tissue sites.

14 Oct 2021

Small portion of COVID-19 patients infectious long-term

In late December 2019, a novel pneumonia-like lung infection was reported in the Chinese province of Hubei. This, in turn, led to the ongoing coronavirus disease-19 (COVID-19) pandemic. COVID-19 is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which is closely related to SARS (Severe Acute Respiratory Syndrome) and MERS (the Middle East Respiratory Syndrome Coronavirus).

13 Oct 2021

How long does natural immunity produced by SARS-CoV-2 infection last?

A new study posted to the bioRxiv* preprint server followed the adaptive immune response in convalescent patients from Swedish and Italian cohorts—which had earlier shown long-lasting adaptive immune responses to the G614 strain—for 15 months. Here, specific antibody levels and neutralizing antibody titers were tested against variants of concern (VOCs).

12 Oct 2021

Vaccinated children induced significantly higher antibody titers than naturally SARS-CoV-2 infected children

A recent preprint discusses the antibody response to the nucleic acid vaccines against SARS-CoV-2 when administered to children aged 7-11 years.

12 Oct 2021

SARS-CoV-2 immune responses in nursing home residents after full vaccination with Pfizer-BioNTech COVID-19 vaccine

A new study assesses antibody and functional T-cell responses at 6 months after complete vaccination with the Pfizer-BioNTech vaccine.

11 Oct 2021

Research finds different antibody responses following COVID vaccination and natural infection

A new study published in the journal Nature attempted to investigate memory B cell evolution 5 months after vaccination with mRNA vaccines such as Moderna (mRNA-1273) or Pfizer-BioNTech (BNT162b2) in SARS-CoV-2 naïve individuals. The study explored various aspects of memory B cell antibody response like neutralizing response, affinity, epitope targeting, and neutralizing breadth.

10 Oct 2021

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

A new paper discusses a new antibody with potent neutralizing activity against the ancestral SARS-CoV-2 strain, as well as newer variants of SARS-CoV-2.

10 Oct 2021

Oral and intranasal COVID-19 vaccines show promising results in hamster model

A new preprint discusses the protective effect of an oral adenovirus-vectored vaccine based on the SARS-CoV-2 spike against viral transmission and disease in hamsters.

8 Oct 2021

BNT162b2 COVID vaccine humoral response substantially reduced after 6 months

The rollout of vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is expanding worldwide. However, little is known about the duration of protection offered by these vaccines. Real-world data on the kinetics of antibodies are beginning to appear, but a holistic picture of immunity duration is still not available.

7 Oct 2021

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

A new study posted to the medRxiv* server and led by Dr. Mattia D'Agostino, Dr. Eleonora Pavoni and Dr. Alice Romagnoli from the Polytechnic University of Marche in Ancona (Italy), a gFET biosensor that uses angiotensin-converting enzyme 2 (ACE2) as a bioreceptor has been put forth as a viable solution.

6 Oct 2021

Durability of immunity to SARS-CoV-2 reinfection

The current study used data on the durability of immunity among evolutionarily close coronavirus relatives of SARS-CoV-2 to estimate times to reinfection.

6 Oct 2021

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Researchers published a study on the expression and functional analyses of a neutralizing mAb with identical variable domains but different constant HCs, representing IgG1-4.

6 Oct 2021

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Your saliva may be able to tell you if you’ve developed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies, suggests a new medRxiv* preprint study. In immunocompromised groups, salivary Immunoglobulin G (IgG) antibody levels were associated with IgG titers in blood serum 3 to 4 weeks after mRNA vaccination.

5 Oct 2021

Study looks at immunosuppressants and COVID vaccine efficacy

Researchers investigate the effects of five established immunosuppressant medications following COVID-19 vaccination.

4 Oct 2021

How durable is the immune response generated from the BNT162b2 vaccine?

In a recent study, researchers analyzed antibody responses to the homologous Wu strain and several other SARS-CoV-2 variants after BNT162b2 vaccination.

4 Oct 2021

Using a new public antibody to understand SARS-CoV-2 neutralization

SARS-CoV-2 infects host cells by binding to the angiotensin convertase 2 receptor (ACE2) on the cell surface through its trimeric spike (S) protein. SARS-CoV enters host human cells through endosomes, while SARS-CoV-2 enters through the cell surface and endosomes. The present study published in the journal “Cell Reports” aimed to understand the mechanisms of SARS-CoV-2 antibody neutralization to facilitate the development of therapeutic interventions for COVID-19.

4 Oct 2021

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

A recent study by a multidisciplinary team of cardiologists and infectious disease specialists at Children's Hospital Colorado (Children's Colorado) found that pediatric patients suffering from Multisystem Inflammatory Syndrome (MIS-C) who received initial, intensified therapy consisting of intravenous immunoglobulin (IVIG) plus Infliximab had improved cardiac outcomes versus those who received IVIG alone.

30 Sep 2021

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

A new study aimed to determine the course of SARS-CoV-2 infection in children suffering from rheumatic disease and were receiving bDMARD treatment.

29 Sep 2021

Immunoglobulin News and Research

Factors contributing to a weak antibody response to the Pfizer COVID-19 vaccine

Common treatment for MIS-C patients likely works by depleting neutrophils

SARS-CoV-2 induces tissue immune memory

Small portion of COVID-19 patients infectious long-term

How long does natural immunity produced by SARS-CoV-2 infection last?

Vaccinated children induced significantly higher antibody titers than naturally SARS-CoV-2 infected children

SARS-CoV-2 immune responses in nursing home residents after full vaccination with Pfizer-BioNTech COVID-19 vaccine

Research finds different antibody responses following COVID vaccination and natural infection

Powerful neutralizing antibody against SARS-CoV-2 variants of concern

Oral and intranasal COVID-19 vaccines show promising results in hamster model

BNT162b2 COVID vaccine humoral response substantially reduced after 6 months

Graphene biosensor in a portable and wireless device for rapid SARS-CoV-2 detection

Durability of immunity to SARS-CoV-2 reinfection

Study shows strong protective effect of IgG3 antibodies in SARS-CoV-2 infection

Humoral responses to SARS-CoV-2 are detectable through saliva, scientists find

Study looks at immunosuppressants and COVID vaccine efficacy

How durable is the immune response generated from the BNT162b2 vaccine?

Using a new public antibody to understand SARS-CoV-2 neutralization

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

Effect of biologic therapy on COVID-19 in children suffering from rheumatic diseases

How Omics Technologies Are Transforming Biological Research and Drug Discovery

How microplastics and bacteria interact to drive antibiotic resistance

Single-cell proteomics: Revealing proteome diversity from cellular heterogeneity to non-canonical biology

Latest News